{"entity":{"id":"binder-targeting-module","kind":"term","name":"Binders as targeting modules","aka":[],"tldr":"A recognition molecule can be used as one component of a larger therapeutic design. Its ability to bind is one property of that component.","summary":"Primary antibody-fragment studies showed how recognition domains can be used outside a complete antibody. Experiments with bispecific T-cell engagers then showed that constructs with similar binding affinity could differ in target-cell lysis because of epitope position and antigen geometry. A binder is therefore a module whose performance must be evaluated in its assembled format. Binding alone does not establish delivery, effector activity or clinical benefit. In a 1993 experiment a single-chain Fv joined to a T-cell receptor signalling chain was expressed in a cytolytic T-cell hybridoma and triggered interleukin-2 secretion and hapten-specific, non-MHC-restricted target-cell lysis (Eshhar et al.), an early demonstration of recognition coupled to activation in one cell model. In a 2022 mouse heart-failure model, lipid nanoparticles carrying CAR mRNA and targeted to CD5 delivered the message to T cells and reduced fibrosis, an example of a binder choosing the cell that receives instructions rather than the cancer cell (Rurik et al.). FDA's March 2024 antibody-drug conjugate clinical pharmacology guidance treats the conjugate and its constituent parts separately.","asOf":"2026-11-10","links":[{"label":"Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli.","url":"https://doi.org/10.1073/pnas.85.16.5879"},{"label":"Naturally occurring antibodies devoid of light chains.","url":"https://doi.org/10.1038/363446a0"},{"label":"Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen.","url":"https://doi.org/10.1007/s00262-010-0844-y"},{"label":"Eshhar et al., 1993: specific activation and targeting of cytotoxic lymphocytes through chimeric single chains","url":"https://doi.org/10.1073/pnas.90.2.720"},{"label":"Rurik et al., 2022: CAR T cells produced in vivo to treat cardiac injury","url":"https://doi.org/10.1126/science.abm0594"},{"label":"FDA: clinical pharmacology considerations for antibody-drug conjugates (March 2024)","url":"https://www.fda.gov/media/155997/download"}],"tags":[],"related":["antibody","epitope","scfv-vhh-formats","binder-format-constraints"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Two inferences about recognition. A gene or RNA signal for a target shows that the target is made, not that its epitope is exposed on living tumour cells. A highly specific binder can also recognise its intended target on healthy tissue; that is on-target, off-tumour injury, not a mistaken molecular address. Evidence that a binder recognises purified protein and living target-positive cells supports recognition in those settings only.","Each connected action adds its own requirement. For an antibody-drug conjugate, FDA's March 2024 clinical pharmacology guidance defines total antibody, unconjugated antibody and unconjugated payload as separate quantities and says its principles may not apply to other types of conjugate. A T-cell engager needs productive contact between two cells, a receptor needs a relevant effect on signalling, and a CAR needs surface expression and target-dependent activation, which Eshhar et al. (1993) first showed in a T-cell hybridoma. Delivery binders choose the cell that receives instructions (Rurik et al., 2022), which can differ from the cancer cell. Attaching a binder shows none of these later steps.","A binder is a part of a design, not a measured quantity, so it has no assay of its own. Binding strength, epitope accessibility and developability belong to the binder-profile record and must be remeasured on the assembled product, because format changes geometry, stability and exposure."],"category":"Biology basics"},"route":"/terms/binder-targeting-module/","neighbours":{"term":[{"id":"antibody","kind":"term","name":"Antibody","route":"/terms/antibody/"},{"id":"binder-affinity-epitope-developability","kind":"term","name":"Binder affinity, epitope and developability","route":"/terms/binder-affinity-epitope-developability/"},{"id":"delivery-target-versus-therapeutic-target","kind":"term","name":"Delivery targets and therapeutic targets","route":"/terms/delivery-target-versus-therapeutic-target/"},{"id":"epitope","kind":"term","name":"Epitope","route":"/terms/epitope/"},{"id":"binder-format-constraints","kind":"term","name":"Format-dependent binder function","route":"/terms/binder-format-constraints/"},{"id":"immune-product-evidence","kind":"term","name":"Immune measurements and product evidence","route":"/terms/immune-product-evidence/"},{"id":"scfv-vhh-formats","kind":"term","name":"Single-chain and single-domain antibody fragments","route":"/terms/scfv-vhh-formats/"}]}}